LAWRENCEVILLE, N.J.,
March 23, 2016 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN) announced today that the
Company will host a conference call to discuss year-end 2015
financial results and provide an update on its development programs
for ThermoDox®, its proprietary heat-activated liposomal
encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector
formulated into a nanoparticle with a non-viral delivery system at
11:00 a.m. EDT on Wednesday, March 30, 2016. To participate in the
call, interested parties may dial 1-800-505-9587
(Toll-Free/North America) or
1-416-204-9524 (International/Toll) and ask for the Celsion
Corporation 4th Quarter 2015 Earnings Call (Conference
Code: 4103364) to register ten minutes before the call is scheduled
to begin. The call will also be broadcast live on the internet at
www.celsion.com.
The call will be archived for replay on Wednesday, March 30, 2016 and will remain
available until Wednesday, April 13,
2016. The replay can be accessed at 1-888-203-1112
(Toll-Free/North America) or
1-719-457-0820 (International/Toll) using Conference Code: 4103364.
An audio replay of the call will also be available on the Company's
website, www.celsion.com, for 30 days after 2:00 p.m. EDT on Wednesday, March 30, 2016.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver cancer and
in Phase II development for the treatment of recurrent chest wall
breast cancer. The pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has two platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies, including TheraPlas™ and
TheraSilence™. For more information on Celsion, visit our
website: www.celsion.com.
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/celsion-corporation-to-hold-year-end-2015-financial-results-conference-call-on-wednesday-march-30-2016-300239801.html
SOURCE Celsion Corporation